Although the AHA Guidelines emphasize CV risk and mortality reductions with statins, ODYSSEY Outcomes provides comparable evidence for alirocumab. How compelling is the evidence for PCSK9 inhibition as a mediator of CV risk and mortality reduction?

Although the AHA Guidelines emphasize CV risk and mortality reductions with statins, ODYSSEY Outcomes provides comparable evidence for alirocumab. How compelling is the evidence for PCSK9 inhibition as a mediator of CV risk and mortality reduction?

CLICK HERE FOR CME CREDIT

Although the AHA Guidelines emphasize CV risk and mortality reductions with statins, ODYSSEY Outcomes provides comparable evidence for alirocumab. How compelling is the evidence for PCSK9 inhibition as a mediator of CV risk and mortality reduction?

Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

J. Wouter Jukema, MD, PhD, FESC, FACC MC

J. Wouter Jukema, MD, PhD, FESC, FACC MC

Professor of Cardiology
Netherlands Heart Foundation
Chairman, Leiden Vascular Medicine
Leiden University Medical Center (LUMC)
Leiden, Netherlands